| ID | 1093 |
| Name of the vaccine | REPEVAX |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 3 years |
| Description of the vaccine | Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine. |
| Name of the manufacturer | Sanofi Pasteur |
| Name of the manufacturing country | United Kingdom |
| Year of manufacture | 2002 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus, pertussis and poliomyelitis. |
| Export | Marketing authorisation holder : Sanofi Pasteur Europe |
| Approval | European Medicine Agency |
| Adjuvant | Aluminium phosphate |
| Repurposing | For pertussis, diphtheria and poliomyelitis. |
| Side effects of vaccine | Pain, redness, swelling, headache, diarrhoea, nausea, myalgia, fever, chills, |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.medicines.org.uk/emc/medicine/15256#gref |
| Other name | NA |
| Additional Links | NA
|